Efficacy, Safety, Tolerability, and Biomarker Effects of GT-02287 in Early Parkinson's Disease
← catalyst calendarNCT07280299 · readout in 681 d
Sponsored by Gain Therapeutics, Inc. (industry) · GANX — their whole pipeline →.
Phase
Phase 2
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
111estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-05-30 | estimated | When the study began enrolling |
| Primary completion | 2028-06-30 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-06-30 | estimated | The whole study's end, after follow-up |
| First posted | 2025-12-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-12-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Parkinson Disease
Interventions
- Drug: Low Dose GT-02287 — also filed as GT-02287 400 or 600 mg/day
- Drug: High Dose GT-02287 — also filed as GT-02287 800 or 1000 mg/day
- Drug: Placebo — also filed as Magnesium aluminometasilicate (MAS)
Primary outcome
what the primary-completion date above is the date OFChange from Baseline to Week 48 in the sum of the Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part II score and Part III score [Efficacy]
measured From baseline to Week 48
Permalink · GANX's whole pipeline · Catalyst calendar · Every registered study · What changed